Passegué E, Weisman IL (2005) Leukemic stem cells: Where do they come from? Stem Cell Rev 1:181–188

Article  PubMed  Google Scholar 

Camacho V, Kuznetsova V, Welner RS (2021) Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. https://doi.org/10.3389/fimmu.2021.772408

Article  PubMed  PubMed Central  Google Scholar 

Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H et al (2015) Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27(5):671–681

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG, Holyoake TL (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 122(19):3335–3339

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232–238

Article  CAS  PubMed  Google Scholar 

Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096–2102

Article  CAS  PubMed  Google Scholar 

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353–1360

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D et al (2012) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120:291–294

Article  CAS  PubMed  Google Scholar 

Iqbal A, Nath UK, Bhattacharyya M, Nag A, Ray SS (2022) Analysis of early molecular response at 3 months in predicting overall response in newly diagnosed patients with chronic myeloid leukemia on Imatinib. J Hematol Allied Sci 2:32–38

Article  Google Scholar 

Nath U, Chetia R, Baveja A (2018) Early molecular response with generic imatinib therapy in sokal/hasford intermediate- & high-risk chronic phase chronic myeloid leukemia patients: a single institution experience from India. Blood 132:4276

Article  Google Scholar 

Kok CH, Saunders VA, Dang P et al (2023) Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer J 13:143

Article  PubMed  PubMed Central  Google Scholar 

Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ et al (2016) TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia 30:1263–1272

Article  CAS  PubMed  Google Scholar 

Yeung DT, Osborn MP, White DL, Branford S, Braley J et al (2015) TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 125(6):915–923

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M et al (2011) IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20(5):661–673

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mauer J, Denson JL, Bruning JC (2015) Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 36:92–101

Article  CAS  PubMed  Google Scholar 

Aggarwal BB, Gupta SC, Kim JH (2012) Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119(3):651–656

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kreutzman A, Yadav B, BrummendorfT H et al (2019) Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. OncoImmunology 8(9):e1638210

Article  PubMed  PubMed Central  Google Scholar 

Petrackova M, Hamsikova E, Duskova M et al (2016) Predictive value of serum cytokine levels in chronic myeloid leukemia patients. Immunol Lett. https://doi.org/10.1016/j.imlet.2016.09.004

Article  PubMed  Google Scholar